Get regular updates to your inbox.
RLF-TD011, an antimicrobial spray, will be granted European Union patent coverage for wound treatment in people with epidermolysis bullosa (EB). The Relief Therapeutics treatment contains highly pure hypochlorous acid, a chemical with antimicrobial and anti-inflammatory properties. RLF-TD011 is marketed as Nexodyn for the management of chronic and acute…
Read more
Treatment with SNT-6935, an experimental compound that acts to reduce the activity of an enzyme that breaks down proteins, reduced skin damage in a lab model of epidermolysis bullosa acquisita (EBA), a study showed. The study, “Granzyme B inhibition reduces autoantibody-induced dermal–epidermal separation in an ex…
Three types of molecules were found to support the production of collagen VII (C7) in patient-derived cell models of recessive dystrophic epidermolysis bullosa (RDEB), according to a recent study. These compounds acted in RDEB caused by premature termination codon (PTC) mutations that produce a shorter, non-functional version of C7,…
Becoming educated and informed about epidermolysis bullosa is a good first step. Here you’ll find general information about the disease, including diagnosis, symptoms, and causes.
It helps to know others have been where you are now. Here’s a collection of our columnists’ words of wisdom to help you along on your EB journey.
There is no cure for EB yet, but there are treatments that can help manage the disease. Learn more about the approved and experimental therapies here.
Get regular updates to your inbox.
